OrthoPediatrics Files Investor Presentation Featuring Updated Guidance and Product Roadmap
KIDS sits 45% above its 52-week low of $14.42.
Summary
OrthoPediatrics filed an investor presentation with updated 2026 guidance and a detailed product pipeline, reinforcing its growth trajectory after a strong Q2 beat.
Key Events · Earnings and Guidance · KIDS
-
Investor Presentation Filed
An investor presentation was filed as Exhibit 99.1 to an 8-K, offering updated financials, a product pipeline overview, and strategic initiatives.
-
2026 Guidance Reiterated
Full-year 2026 revenue guidance stands at $265–269 million (12–14% growth), with adjusted EBITDA of approximately $25 million and free cash flow breakeven expected.
-
Product Super-Cycle Detailed
A multi-year product launch super-cycle is outlined, with systems such as 3P Small|Mini, Tractor Fix, and VerAxis Scoliosis expected from Q3 2026 through Q4 2027.
-
OPSB Expansion Plans
The OPSB bracing business plans to enter 6 new markets in 2026 and 8 in 2027, targeting 27 territories by 2027 out of a total of 80 target territories.
Analysis · KIDS · Industrial Applications And Services
Alongside its Q2 2026 earnings, OrthoPediatrics filed an investor presentation that updates full-year guidance to $265–269 million in revenue and approximately $25 million in adjusted EBITDA. The deck maps out a multi-year product launch super-cycle—several new systems are slated for the next 18 months—and details expansion plans for the OPSB bracing business. Investors gain a comprehensive view of the growth strategy and near-term catalysts.
At the time of this filing, KIDS was trading at $20.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $536.3M. The 52-week trading range was $14.42 to $22.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.